Maintenance therapy in NSCLC: Why? to whom? Which agent?

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Novello, Silvia ^a   Milella, Michele ^b   Tiseo, Marcello ^c   Banna, Giuseppe ^d   Cortinovis, Diego ^e   Di Maio, Massimo ^f   Garassino, Marina ^g   Maione, Paolo ^h   Martelli, Olga ⁱ   Vavalà, Tiziana ^a   Bria, Emilio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Department of Medical Oncology AOU   (Italy)

^d CANNIZZARO HOSPITAL   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h San Giuseppe Moscati Hospital Avellino   (Italy)

ⁱ SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; VANDETANIB; VINBLASTINE; ANTINEOPLASTIC AGENT;

CANCER THERAPY; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; HUMAN; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; LUNG TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS;

EID: 79955656558     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-50     Document Type: Review

References (47)

1. Cancer statistics 2010. A Jemal R Siegel J Xu E Ward, CA Cancer J Clin 2010 60
2. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. R Govindan N Page D Morgensztern W Read R Tierney A Vlahiotis EL Spitznagel J Piccirillo, J Clin Oncol 2006 24 4539 4544 10.1200/JCO.2005.04.4859 17008692 (Pubitemid 46630948)
3. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. P Yang MS Allen MC Aubry JA Wampfler RS Marks ES Edell S Thibodeau AA Adjei J Jett C Deschamps, Chest 2005 128 452 462 10.1378/chest.128.1.452 16002972 (Pubitemid 40994510)
4. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small cell lung cancer: AVAIL. M Reck J Von Pawel P Zatloukal R Ramlau V Gorbounova N Leighl Mezger J V Archer N Moore C Manegold, J Clin Oncol 2009 27 1227 1234 10.1200/JCO.2007.14. 5466 19188680
5. Paclitaxel-Carboplatin alone or with bevacizumab for non-small cell lung cancer. A Sandler R Gray MC Perry J Brhamer JH Schiller A Dowlati R Lilembaum DH Johnson, New England J Med 2006 355 2542 2550 10.1056/NEJMoa061884 (Pubitemid 44917502)
6. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. R Pirker A Pereira Szczesna jr M Krzakowski R Ramlau I Vynnychenko K Park CT Yu V Ganul JK Roh K O'Byrne F de Marinis W Eberhardt T Goddemeier M Emig U Gatzemeier, Lancet 2009 373 1525 1531 10.1016/S0140-6736(09)60569-9 19410716
7. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. FA Sheperd J Dancey R Ramlau K Mattson R Gralla M O'Rourke N Levitan L Gressot M Vincent R Burkes S Coughlin Y Kim J Berille, J Clin Oncol 2000 18 2095 2103 10811675 (Pubitemid 30324363)
8. Randomized phase III trial of docetaxel versus vinorlbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. FV Fossella R DeVore RN Kerr J Crawford RR Natale F Dunphy L Kalman V Miller JS Lee M Moore D Gandara D Karp E Vokes M Kris Y Kim F Gamza L Hammershaimb, J Clin Oncol 2003 18 2354 2
9. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. TA Hensing MJ Schell JH Lee MA Socinski, Lung Cancer 2005 47 2 253 9 10.1016/j.lungcan.2004.07.040 15639724 (Pubitemid 40082168)
10. Potential treatment options after first line chemotherapy for advanced NSCLC: maintenance treatment or early second line? C Gridelli P Maione A Rossi ML Ferrara MA Bareschino C Schettino PC Sacco F Ciardiello, The Oncologist 2009 14 137 47 10.1634/theoncologist.2008-0152 19190239
11. NCCN practice guidelines in oncology v.2. 2010 http://www.nccn.org
12. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. American Society of Clinical Oncology, J Clin Oncol 1997 15 2996 3018 9256144
13. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. IE Smith ME O'Brien DC Talbot,, et al. J Clin Oncol 2001 19 1336 1343 11230476 (Pubitemid 32202538)
14. Phase III trial comparing a defined duration o therapy versus continuous therapy followed by a second-line therapy in advanced stage IIIB/IV non small cell lung cancer. MA Socinski MJ SChell E Peterman K Bakri S Yates R Gitten P Unger J Lee JH Lee M Tynan M Moore MS Kies, J Clin Oncol 2002 20 1335 1343 10.1200/JCO.20.5.1335 11870177 (Pubitemid 34182817)
15. Palliative chemotherapy beyond three courses conveys no survival benefit or consistent quality of life benefits in advanced non small cell lung cancer. C Von Plessen B Bergman O Andresen RM Bremnes S Sundstrom M Gilleryd R Stephens J Vilsvik U Aasebo S Sorenson, Br J Cancer 2006 95 966 973 10.1038/sj.bjc.6603383 17047644 (Pubitemid 44606820)
16. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. JO Park SW Kim JS Ahn C Suh JS Lee JS Jang EK Cho SH Yang JH Choi DS Heo YH Yun JW Lee K Park, J Clin Oncol 2007 25 5233 5239 10.1200/JCO.2007.10. 8134 18024869 (Pubitemid 350232255)
17. American Society of clinical Oncology treatment of unresectable non-small cell lung cancer guideline. Update 2003. DG Pfister DH Johnson CG Azzoli W Sause TJ Smith SJr Baker J Olak D Stover JR Strawn AT Turrisi MR Somerfield, J Clin Oncol 2004 22 330 353 14691125 (Pubitemid 41095099)
18. American Society of clinical Oncology practice guideline update on chemotherapy for stage IV Non-small cell lung cancer. CG Azzoli S Baker S Termin W Pao T Aliff J Brahmer DH Johnson JL Laskin G Masters D Milton L Nordquist DG Pfister S Piantadosi JH Schiller R Smith YJ Smith JR Strawn D Trent G Giaccone, J Clin Oncol 2009 36 6251 6266
19. Cisplatin and gemcitabine first line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. T Brodowicz M Krzakowski M Zwitter V Tzekov R Ramlau N Ghilezn T Ciuleanu B Cucevic K Gyurkovits E Ulsperger J Jassem M Grgic P Saip M Szila N Oskina V Soldatenkova C Zielinsk M Wenczl, Lung Cancer 2006 52 155 163 10.1016/j.lungcan.2006.01.006 16569462
20. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). CP Belani H Waterhouse H Ghazal,, et al. J Clin Oncol 2010 28 15s bstr 7506
21. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. M Perol C Chouaid J Milleron,, et al. J Clin Oncol 2010 28 15s bstr 7507
22. Multicenter, randomized trial for stage IIIB or IV non small cell lung cancer using weekly paclitaxel or observation. CP Belani J Barstis MC Perry RV La Rocca SR Nattam D Rinaldi R Clark GM Mills, J Clin Oncol 2003 21 2933 2939 10.1200/JCO.2003.02.563 12885812 (Pubitemid 46621844)
23. A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. JH Goldie AJ Coldman, Cancer Treat Rep 1979 63 1727 17233 526911
24. Maintenance therapy in advanced non small cell lung cancer. LE Coate FA Shepherd, JTO 2010 5 5 723 734
25. Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. V Westeel E Quoix D Moro Sibilot M Mercier JL Breton D Debieuvre P Richard MA Haller B Milleron D Herman MC Level M Puyraveau A Depierre, J Natl Cancer Inst 2005 97 499 506 10.1093/jnci/dji096 15812075 (Pubitemid 40590431)
26. Phase III study of immediate versus delayed docetaxel after front line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. PM Fidias SR Dakhil AP Lyss DM Loesch DM Waterhouse JL Bromund R Chen MH Kazmierski J Treat CK Obasaju M Marciniak J Gill JH Schiller, J Clin Oncol 2009 27 591 8 19075278
27. Maintenance pemetrexed plus best supportive care vesus placebo plus best supportive care for non-small cell lung cancer: a randomized double-blind, phase III study. T Ciuleanu T Brodowicz JH Zielinski C Kim M Krzakowski E Laack YL Wu I Bover S Begbie V Tzekova B Cucevic J Pereira SH Yang J Madhavan KP Sugarman P Peterson WJ John K Krejcy CP Belani, Lancet 2009 374 1432 4 10.1016/S0140-6736(09)61497-5 19767093
28. The differential efficacy of pemetrexed according to NSCLC histology, a review of two phase III studies. GV Scagliotti N Hanna F Fossella K Sugarman J Blatter P Peterson L Simms FA Shepherd, Oncologist 2009 14 253 63 10.1634/theoncologist.2008-0232 19221167
29. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced non-small cell lung cancer. GV Scagliotti P Parikh Von Pawel J Biesma J Vansteenkiste C Manegold P Serwatowski U Gatzemeier R Digumarti M Zukin JS Lee A Mellemgaard K Park S Patil J Rolski T Goksel F de Marinis L Simms K PSugarman D Gandara, J Clin Oncol 2008 26 3543 51 10.1200/JCO.2007.15.0375 18506025
30. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. F Cappuzzo BP Coudert R Wierzbicki,, et al. Presented at the 13th World Conference on Lung Cancer, July 31 to August 4, 2009 bstract A2.1
31. Erlotinib as maintenance treatment in advanced non-small-cell lung ancer: a multicentre, randomized, placebo-controlled phase 3 study. F Cappuzzo L Ciuleanu L Stelmakh S Cicenas A Szczésna E Juhsz E Esteban O Molinier W Brugger I Melezínek G Klingelschmitt B Klughammer G Giaccone, Lancet 2010 11 521 529 10.1016/S1470-2045(10)70112-1
32. Overall survival in ATLAS, a phase IIIB study comparing bevacizumab therapy +/- Erlotinib after completion of chemotherapy with bevacizumab for first line treatment of locally advanced, recurrent metastatic non-small-cell lung cancer. F Kabbinavar Va Miller BE Johnson,, et al. J Clin Oncol 2010 28 15s bstr 7526
33. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). RM Gaafar V Surmont GV Scagliotti,, et al. J Clin Oncol 2010 28 15s bstr 7518
34. Randomized phase II trial of gemcitabine plus weekly versus three weekly paclitaxel in previously untreated advanced non small cell lung cancer. CP Belani S Dakhil DM Waterhouse RH Clark MJ Monberg Z Ye CK Obasaju, Ann Oncol 2007 18 1 110 115 17043094 (Pubitemid 46152509)
35. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. LG Paz-Ares S Altug AT Vaury JC Jaime F Russo C Visseren-Grul, BMC Cancer 2010 8 10 85
36. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced non squamous non-small-cell-lung cancer. R Klein R Wielage C Muehlenbein AM Liepa S Babineaux A Lawson L Schwartzberg, J Thorac Oncol 2010 5 8 1263 72 10.1097/JTO.0b013e3181e15d16 20581708
37. Maintenance therapy for advanced Non-small cell lung cancer: current status, controversies and emerging consensus. T Owokikonoko SS Ramalingam CP Belani, Clin Cancer Res 2010 16 9
38. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. MF Burger MA Brady JL Bookman,, et al. J Clin Oncol (Meeting Abstracts) 2010 28 18 BA1
39. Clinical Trials. http://www.clinicaltrials.gov
40. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. R Rosell T Moran C Queralt,, et al. NEJM 2009 361 10 958 96 10.1056/ NEJMoa0904554 19692684
41. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. S Maheswaran LV Sequist S Nagrath L Ulkus B Brannigan CV Collura E Inserra AJ Iafrate DW Bell A Muzikansky D Irimia J Settleman RG Tompkins TJ Lynch M Toner DA Haber, NEJM 2008 359 366 377 10.1056/NEJMoa0800668 18596266
42. Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. R Rosell MA Molina C Costa,, et al. J Clin Oncol 2010 28 15s bstr 7514
43. Impact of clinical and molecualr predictors of benefit from erlotinib in advanced non-small cell lung cancer on cot-effectiveness. PA Bradbury D Tu L Seymour,, et al. J Clin Oncol 2008 26 344s bstr 6531
44. Treatment Rationale and Study Design for the PointBreak Study: Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/ Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. JD Patel P Bonomi MA Socinski R Govindan S Hong C Obasaju EJ Pennella AC Girvan SC Guba, Clinical Lung Cancer 2009 10 4 252 256 10.3816/CLC.2009.n.035 19632943
45. Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer of nonsquamous histology. R Zinner S Saxman G Peng,, et al. J Clin Oncol 2010 28 15s PS290
46. Randomized phase IIb trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. C Butts N Murray A Maksymiuk G Goss E Marshall D Soulières Y Cormier P Ellis A Price R Sawhney M Davis J Mansi C Smith D Vergidis P Ellis M MacNeil M Palmer, J Clin Oncol 2005 23 6674 6681 10.1200/JCO.2005.13.011 16170175 (Pubitemid 46190262)
47. Evolving treatment algorithms for advanced non-small-cell lung cancer:2009 Looking toward 2012. DR Gandara PC Mack PN Lara RS Herbst, Clin Lung Cancer 2009 10 6 392 4 10.3816/CLC.2009.n.074 19900855